Dynavax Technologies (NASDAQ:DVAX) Reaches New 12-Month High – Should You Buy?

Dynavax Technologies Corporation (NASDAQ:DVAX) hit a new 52-week high during mid-day trading on Wednesday . The company traded as high as $15.50 and last traded at $15.4250, with a volume of 4300597 shares changing hands. The stock had previously closed at $11.13.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (d)” rating on shares of Dynavax Technologies in a report on Wednesday, October 8th. Three analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $24.33.

Dynavax Technologies Trading Up 38.7%

The company has a debt-to-equity ratio of 0.41, a current ratio of 7.62 and a quick ratio of 6.94. The company has a market capitalization of $1.81 billion, a price-to-earnings ratio of -41.72 and a beta of 0.89. The business’s 50-day moving average price is $10.77 and its two-hundred day moving average price is $10.48.

Dynavax Technologies (NASDAQ:DVAX) last announced its quarterly earnings data on Wednesday, November 5th. The biopharmaceutical company reported $0.21 earnings per share for the quarter, beating the consensus estimate of $0.14 by $0.07. The firm had revenue of $94.88 million during the quarter, compared to analysts’ expectations of $94.00 million. Dynavax Technologies had a positive return on equity of 7.18% and a negative net margin of 13.13%. Research analysts predict that Dynavax Technologies Corporation will post 0.32 earnings per share for the current year.

Hedge Funds Weigh In On Dynavax Technologies

Hedge funds and other institutional investors have recently made changes to their positions in the company. Capital Fund Management S.A. acquired a new position in Dynavax Technologies during the second quarter worth about $1,669,000. Jacobs Levy Equity Management Inc. acquired a new position in Dynavax Technologies during the 1st quarter worth about $2,477,000. Squarepoint Ops LLC boosted its holdings in Dynavax Technologies by 222.3% in the second quarter. Squarepoint Ops LLC now owns 435,577 shares of the biopharmaceutical company’s stock valued at $4,321,000 after acquiring an additional 300,421 shares during the last quarter. Hudson Bay Capital Management LP raised its stake in Dynavax Technologies by 46.4% during the second quarter. Hudson Bay Capital Management LP now owns 541,600 shares of the biopharmaceutical company’s stock worth $5,373,000 after buying an additional 171,700 shares during the last quarter. Finally, American Century Companies Inc. lifted its stake in shares of Dynavax Technologies by 28.7% in the 2nd quarter. American Century Companies Inc. now owns 375,716 shares of the biopharmaceutical company’s stock valued at $3,727,000 after purchasing an additional 83,833 shares during the period. 96.96% of the stock is currently owned by institutional investors and hedge funds.

About Dynavax Technologies

Dynavax Technologies Corporation is a biopharmaceutical company focused on the development and commercialization of novel vaccines and immunotherapies. Headquartered in Emeryville, California, the company specializes in leveraging its proprietary Toll-like receptor (TLR) agonist platform to enhance immune responses. Its lead product, HEPLISAV-B, is a two-dose hepatitis B vaccine approved by the U.S. Food and Drug Administration that incorporates the CpG 1018 adjuvant to stimulate a rapid and robust antibody response in adults.

Founded in 1993, Dynavax has built a pipeline that extends beyond hepatitis B to include candidates targeting seasonal influenza, respiratory syncytial virus (RSV) and emerging infectious diseases.